Bacil Pharma Ltd has accepted the resignation of Dikshant Singh Panwar as Whole-Time Company Secretary and Compliance Officer, effective October 8, 2026.

The resignation was tendered due to increasing personal and professional commitments that require dedicated attention, making it difficult for Panwar to continue fulfilling the demands of the role. The company confirmed the acceptance of the resignation on the same date it was submitted.

Regulatory compliance and next steps

The intimation was filed with BSE Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Bacil Pharma stated that it is currently in the process of taking necessary steps to appoint a suitable person as Company Secretary and Compliance Officer, in accordance with the applicable provisions of the Companies Act, 2013, and SEBI (LODR) Regulations, 2015.

Key details of the departure

Panwar’s resignation letter cited unavoidable circumstances as the primary driver for his exit. He expressed sincere appreciation to the Board and the company for the opportunity. The company’s Director, Chaitali Kalpataru Shah, signed off on the disclosure to the exchange.

Bacil Pharma Limited concluded its 39th Annual General Meeting on September 23, 2026, approving key governance changes including the elevation of Chaitali Kalpataru Shah to Managing Director and the appointment of new statutory auditors. The meeting, conducted via video conferencing, saw attendance from 66 members.

Governance and leadership updates

The shareholders passed a special resolution to change the designation of Chaitali Kalpataru Shah (DIN: 11167778) from Executive Director to Managing Director. Additionally, the company reappointed three independent directors for another term:

• Omprakash Pyarelal Sonar (DIN: 11031877)
• Vivek Mukesh Yadav (DIN: 11033957)
• Mahesh Singh (DIN: 11814569)

Anil Singh (DIN: 09338444) was also reappointed as a Non-Executive Non-Independent Director. These appointments signal a continuation of the current board's strategic direction.

Financial oversight and capital structure

The meeting addressed financial reporting and capital adjustments. Shareholders approved the adoption of the audited financial statements for the fiscal year ended March 31, 2026. A significant operational change involved the appointment of M/s Sarang Shivajirao Chavan & Associates Chartered Accountants (FRN: 159649W) as the new Statutory Auditors, replacing the previous firm.

Furthermore, an ordinary resolution was passed to increase the authorized share capital of the company, necessitating an alteration to the capital clause in its memorandum of association. This move typically provides flexibility for future fundraising or corporate actions.

Voting results and compliance details

The AGM was held in compliance with Ministry of Corporate Affairs and SEBI circulars allowing virtual meetings. Voting was facilitated through remote e-voting by NSDL, with a scrutinizer appointed to ensure transparency. The scrutinizer report, submitted on September 24, 2026, confirmed that all resolutions were passed with requisite majority.

The detailed voting outcomes for key resolutions are as follows:

The scrutinizer, CS Ramesh Chandra Bagdi of Ramesh Chandra Bagdi & Associates, verified the results using data from NSDL. The e-voting reports containing lists of members who voted for and against each resolution have been sealed and handed over to the Company Secretary for safekeeping.